March 25, 2013
/PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced today that it secured
in debt financing with Hercules Technology Growth Capital (NYSE: HTGC), to fund the company's capital budget through late 2014.
"This debt financing extends our cash runway well into late 2014 at a critical time in our clinical product development cycle. We have multiple NSI-566 cell therapy clinical trials planned this year, building on our successful ALS Phase I trial, including the upcoming phase II ALS in the U.S.; both chronic and acute spinal cord injury in the U.S. and
, respectively; ALS in
, and stroke in
, in addition to completing the NSI-189/Phase Ib trial in major depressive disorder," said Neuralstem's President and CEO
. "We are pleased to have the support of leading life sciences and technology investor, Hercules."
"Neuralstem's unique stem cell platform has the potential to address a serious unmet medical need in the ALS and spinal cord injury patient populations, as well as other indications. The team's progress to date is the result of years of meticulous research and development. We are proud to be a strong financial partner," said
, managing director at Hercules.
The funding of
, which closed on
March 22, 2013
, is in the form of a secured note which is repayable in installments over 42 months following an interest-only period of nine months and up to 12 months upon funding of a second tranche. The note bears interest at a prime-based variable rate. In addition, Neuralstem issued Hercules 648,798 warrants to purchase shares of Neuralstem common stock at an exercise price of
per share. The second tranche of
will be made available to the company, at the company's option until
September 30, 2013
, subject to certain conditions. Further information with respect to the loan agreement with Hercules is contained in a Current Report on Form 8-K filed with the Securities and Exchange Commission.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities referenced herein in any jurisdiction to any person. The warrants and underlying shares issued in connection with the transactions have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in
the United States
absent registration under the Securities Act and applicable state securities laws or an applicable exemption from those registration requirements.
TriPoint Global Equities, LLC was the placement agent for the transaction.